

*JN*

immunodeficiency virus type 1 (HIV-1), wherein said proteins are p12 and p25 proteins of HIV-1.

19. (Amended) [An isolated and purified] A mixture of antibodies which bind with isolated and purified proteins of human immunodeficiency virus type 1 (HIV-1), wherein said proteins are p18 and p25 proteins of HIV-1.

*JN*

20. (Amended) [An isolated and purified] A mixture of antibodies which bind with isolated and purified proteins of human immunodeficiency virus type 1 (HIV-1), wherein said proteins are p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1.

*JN*

29. (Amended) An [isolated and purified] immunological complex comprising [a] an isolated and purified protein of human immunodeficiency virus type 1 (HIV-1) and an antibody against said protein, which antibody binds with said protein, wherein said protein is p12 protein of HIV-1.

*JN*

30. (Amended) An [isolated and purified] immunological complex comprising [a] an isolated and purified protein of human immunodeficiency virus type 1 (HIV-1) and an antibody against said protein, which antibody binds with said protein, wherein said protein is p18 protein of HIV-1.

---

REMARKS

Applicants request consideration of the Amendment filed October 11, 1994, the Information Disclosure Statement filed November 9, 1994, the entry of the above amendment to the claims, and consideration of the following remarks and exhibit.

LAW OFFICES  
FINNEGAN, HENDERSON,  
FARABOW, GARRETT  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000